logo
  1. Home
  2. Stocks
  3. Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Share Price

Mid Cap | Pharmaceuticals and health care | NSE: GLENMARK | BSE: 532296

₹1,499.85 image-45.40 (-2.94 %)

Last Updated: 04 Apr 2025 03:57 PM

Technicalsimage BULLISHimage

Overview

Open (₹) 1,545.25

High (₹) 1,545.25

Low (₹) 1,469.00

Prev. Close (₹) 1,545.25

Volume 8,48,410

VWAP (₹) 1,286.16

ROCE (%) 17.01

Industry P/E 44.73

TTM P/E -240.75

P/B Ratio 5.39

Market Cap (₹) Cr.42,323.99

Dividend Yield (%)0.17

EPS (₹) -53.22

ROE-19.14%

Sales Growth (%) -9.06

Profit Growth (%)-479.84

Day Range

1,545.251,545.25

L
H

52 Week Range

985.601,830.05

L
H

Historical Returns

Returns (6M)

-10.46 %

Returns (1Y)

47.42 %

Returns (3Y)

215.69 %

Returns (5Y)

557.97 %

Returns (6M)

-10.46 %

Returns (1Y)

47.42 %

Returns (3Y)

215.69 %

Returns (5Y)

557.97 %

SWOT Analysis

  • Effectively using its capital to generate profits - ROCE improved in the last year
  • Company with Low Debt
  • Strong short-term momentum: Price above short-term moving averages (EMA_10)
  • Strong long-term momentum: Price above long-term moving averages (EMA_200)
  • Price above the pivot point indicates bullish sentiment.
  • Price above EMA and SMA (50) indicates bullish momentum.

Technicals
info_icon

Technical Rating

Trendimage  BULLISH
Moving Averages
Technical Indicators
Bullish
Bullish

RSI 38.17

MFI 14.49

ATR 60.62

Commodity Channel Index -117.31

ROC125 -24.38

ROC21 -11.73

Williams %R -98.75

Resistance & Support
info_icon

TypeResistance 1 Resistance 2 Resistance 3 PP Support 1 Support 2 Support 3
Current1,300.801,322.651,335.301,288.151,266.301,253.651,231.80
Week Ago1,339.611,378.431,403.211,314.831,276.011,251.231,212.41
Month Ago1,422.091,444.971,471.941,395.121,372.241,345.271,322.39

EMA & SMA
info_icon

1499.85

Current Price

EMA & SMApin

Bullish Moving Averages

18

Bearish Moving Averages

2

5 Day 1304.88

9 Day 1341.97

10 Day 1331.13

12 Day 1367.99

14 Day 1384.52

20 Day 1401.11

26 Day 1409.13

50 Day 1477.74

100 Day 1552.44

200 Day 1480.44

Deals & Announcements

Bulk and Block Deals

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
UBS AGblockSell25 Mar, 2025₹1,492.652,64,465NSE
INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.blockBuy25 Mar, 2025₹1,492.652,64,465NSE
UBS PRINCIPAL CAPITAL ASIA LIMITEDblockSell23 Jan, 2025₹1,510.006,71,394NSE
UBS AGblockBuy23 Jan, 2025₹1,510.006,71,394NSE
ISHARES INDIA SC MAURITIUS COMPANYblockSell03 Oct, 2022₹388.6538,131NSE
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell03 Oct, 2022₹388.652,93,902NSE
ISHARES MSCI INDIA SMALL-CAP ETFblockBuy03 Oct, 2022₹388.6538,131NSE
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy03 Oct, 2022₹388.652,93,902NSE
CENTILLION RESEARCH INDIA LLPbulkSell24 Jun, 2020₹465.6315,02,024NSE
CENTILLION RESEARCH INDIA LLPbulkBuy24 Jun, 2020₹465.4615,02,024NSE
SURJECTIVE RESEARCH CAPITAL LLPbulkSell23 Jun, 2020₹495.8827,80,541NSE
SHADOWFAX ADVERTISERS PRIVATE LIMITEDbulkSell23 Jun, 2020₹500.8134,49,645NSE
HRTI PRIVATE LIMITEDbulkSell23 Jun, 2020₹498.6319,05,536NSE
GRAVITON RESEARCH CAPITAL LLPbulkSell23 Jun, 2020₹493.1421,66,286NSE
CENTILLION RESEARCH INDIA LLPbulkSell23 Jun, 2020₹494.8024,31,725NSE
ALPHAGREP SECURITIES PRIVATE LIMITEDbulkSell23 Jun, 2020₹499.4129,18,705NSE
SURJECTIVE RESEARCH CAPITAL LLPbulkBuy23 Jun, 2020₹495.6427,20,020NSE
SHADOWFAX ADVERTISERS PRIVATE LIMITEDbulkBuy23 Jun, 2020₹500.6334,49,645NSE

Insider Trading

DateNameActionAvg. PriceQuantityDeal Value
25 Sept, 2023Mr. Praveen D KurkalDisposal₹852.001,000NSE
25 Sept, 2023Mr. Praveen D KurkalDisposal₹852.001,000NSE
25 Sept, 2023Mr. Praveen D KurkalDisposal₹851.02500NSE
24 Nov, 2021ROBIN PINTOAcquisition₹490.19250NSE
17 Nov, 2021SRIDHAR GORTHIDisposal₹535.68559NSE
29 Sept, 2021NEHA SALDANHAAcquisition₹20,000NSE
29 Sept, 2021RAYNA MARIE SALDANHADisposal₹10,000NSE
29 Sept, 2021AISHA LOUISE SALDANHADisposal₹10,000NSE
27 Sept, 2021GLENN SALDANHAAcquisition₹513.029,800NSE
23 Sept, 2021CHERYLANN PINTOAcquisition₹512.871,950NSE

Corporate Actions

Announcement DateSubjectEx - DateRecord Date
24 May, 2024Rs.2.5000 per share(250%)Final Dividend13 Sept, 202401 Jan, 1970
19 May, 2023Rs.2.5000 per share(250%)Final Dividend18 Sept, 202301 Jan, 1970
30 May, 2022Rs.2.5000 per share(250%)Final Dividend12 Sept, 202201 Jan, 1970

Announcements

DateSourceDetail
01 Apr, 2025BSE IndiaGlenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)
01 Apr, 2025NSE IndiaGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 01, 2025, titled ""Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)"".
28 Mar, 2025NSE IndiaGlenmark Pharmaceuticals Limited has informed the Exchange about General Updates
27 Mar, 2025NSE IndiaGlenmark Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
26 Mar, 2025NSE IndiaGLENMARK PHARMACEUTICALS LIMITED has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot
26 Mar, 2025NSE IndiaGlenmark Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot
26 Mar, 2025BSE IndiaIntimation regarding Postal Ballot Notice
20 Mar, 2025NSE IndiaGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 20, 2025, titled ""Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%(OTC)"".
20 Mar, 2025BSE IndiaGlenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
12 Mar, 2025NSE IndiaGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 12, 2025, titled ""Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India"".

Board Meetings

PurposeDetailsMeeting DateBroadcast Date
Quarterly Results--04 Feb, 202514 Feb, 2025
Quarterly Results--31 Oct, 202414 Nov, 2024
Quarterly Results--01 Aug, 202414 Aug, 2024
Audited Results & Final Dividend--15 May, 202424 May, 2024
Quarterly Results--31 Jan, 202414 Feb, 2024
Quarterly Results--02 Nov, 202310 Nov, 2023
Quarterly Results--02 Aug, 202311 Aug, 2023
Audited Results & Final Dividend--04 May, 202319 May, 2023
Quarterly Results--16 Jan, 202310 Feb, 2023
Quarterly Results--03 Nov, 202211 Nov, 2022

Share Holding Pattern

Loading...

Loading...

Owner NameDec, 2024Dec, 2023Dec, 2022Dec, 2021Dec, 2020
Promoter Group46.65%46.65%46.65%46.65%46.63%
Foreign Institutions +23.51%23.71%23.19%24.18%26.48%
Domestic Institutions +13.85%10.92%10.69%10.88%9.43%
Government0.04%0.04%0.04%0%0%
Public15.95%18.68%19.43%18.29%17.46%
Others0%0%0%0%0%

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 7891.12 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2024.

Parent Organisation

Not Applicable

Founded

1977

Managing Director

Mr. Glenn Saldanha

NSE Symbol

GLENMARK

Glenmark Pharmaceuticals Management

NameDesignation
Mr. Glenn SaldanhaChairman & Managing Director
Mrs. Cherylann PintoExecutive Director - Corporate Affairs
Mr. V S ManiExecutive Director & Global CFO
Mrs. B E SaldanhaNon Executive Director
Ms. Saira RamasastryInd. Non-Executive Director
Mrs. Vijayalakshmi IyerInd. Non-Executive Director
Mr. Rajesh V DesaiInd. Non-Executive Director
Mr. Dipankar BhattacharjeeInd. Non-Executive Director

Peer Comparison

StocksMarket CapMarket Price52 Week Low-High
Sun Pharmaceutical Industries₹4,10,130.32₹1,709.35 image
₹1,770.00(-3.43%)		₹1,376.750 - ₹1,960.200
Divi's Laboratories₹1,45,552.44₹5,482.85 image
₹5,763.00(-4.86%)		₹3,613.550 - ₹6,448.750
Cipla₹1,14,298.01₹1,415.25 image
₹1,495.70(-5.38%)		₹1,317.600 - ₹1,702.000
Torrent Pharmaceuticals₹1,11,230.09₹3,286.50 image
₹3,247.70(1.19%)		₹2,508.650 - ₹3,589.950
Mankind Pharma₹1,01,131.25₹2,451.20 image
₹2,427.70(0.97%)		₹1,910.100 - ₹3,050.000

FAQs on Glenmark Pharmaceuticals

What is the share price of Glenmark Pharmaceuticals?

The share price of Glenmark Pharmaceuticals on 04 Apr, 2025 is ₹ 1,499.85.

What is 52W high and 52W low share price of Glenmark Pharmaceuticals?

The highest and lowest 52W share prices of Glenmark Pharmaceuticals are ₹ 1830.050 and ₹ 978.900

What is the market cap of Glenmark Pharmaceuticals?

The market capitalization of Glenmark Pharmaceuticals as of 04 Apr, 2025 is ₹ 42,323.99 Crores

What is the P/E ratio of Glenmark Pharmaceuticals?

The current P/E ratio of Glenmark Pharmaceuticals as of 04 Apr, 2025 is 44.73

What is the PB ratio of Glenmark Pharmaceuticals?

The PB ratio of Glenmark Pharmaceuticals as of 04 Apr, 2025 is 5.39

Top Gainers

GLOBUSCON

Globus Power Generation

₹18.07image

₹15.14 (0.19%)

SHANTIDENM

Shanti Spintex

₹66.60image

₹57.80 (0.15%)

DEL

Dhanashree Electronics

₹88.74image

₹73.95 (0.20%)

PARSHVA

Parshva Enterprises

₹197.50image

₹167.35 (0.18%)

Top Losers

GOLDIAM

Goldiam International

₹307.35image

₹368.55 (-0.17%)

EVERFIN

Everlon Financials

₹108.20image

₹127.00 (-0.15%)

KBCGLOBAL

KBC Global

₹0.54image

₹1.03 (-0.48%)

GRWRHITECH

Garware Hi-Tech Films

₹2,705.55image

₹3,206.90 (-0.16%)

Market Indices

Sensex

₹75,364.69image

₹76,295.36 (-0.01%)

Source : Dion Global Solutions Limited